Definium Therapeutics (DFTX) Cash & Equivalents (2020 - 2026)

Definium Therapeutics (DFTX) has 6 years of Cash & Equivalents data on file, last reported at $257.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $257.2 million, up 219.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $257.2 million (up 219.9% YoY), and the FY2025 annual result was $255.3 million, down 5.97% from the prior year.
• Cash & Equivalents advanced to $257.2 million in Q1 2026 per DFTX's latest filing, from $255.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $295.3 million in Q3 2024 and troughed at $20.0 million in Q3 2025.
• A 5-year average of $159.0 million and a median of $130.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 93.24% in 2025, then surged 219.9% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $131.7 million in 2022, then decreased by 24.29% to $99.7 million in 2023, then soared by 172.31% to $271.5 million in 2024, then fell by 5.97% to $255.3 million in 2025, then advanced by 0.74% to $257.2 million in 2026.
• Business Quant data shows DFTX's Cash & Equivalents at $257.2 million in Q1 2026, $255.3 million in Q4 2025, and $20.0 million in Q3 2025.